Overview
KPTI market data
Price History
KPTI price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for KPTI. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Karyopharm Therapeutics Inc. (KPTI)SEC EDGAR · Jul 17, 2026, 9:01 PM
Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026Benzinga · Jun 2, 2026, 2:10 PM
Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual MeetingBenzinga · Jun 2, 2026, 1:03 PM
Karyopharm Therapeutics To Host Conference Call On June 2 To Discuss Results From Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis And To Follow Dr. Mascarenhas' Oral Presentation Of Results At 2026 ASCO Annual MeetingBenzinga · Jun 1, 2026, 11:33 AM
Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.Benzinga · May 15, 2026, 3:52 PM
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call TranscriptBenzinga · May 14, 2026, 1:37 PM
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M EstBenzinga · May 14, 2026, 11:37 AM
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M EstimateBenzinga · May 14, 2026, 11:35 AM
Earnings Scheduled For May 14, 2026Benzinga · May 14, 2026, 11:11 AM